IntroductionSince their approval by the Food and Drug Administration (FDA) in 1998, selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) have accounted for a growing proportion of prescriptions for the class containing all nonsteroidal anti-inflammatory drugs (NSAIDs).1 COX-2 inhibitors include drugs such as celecoxib (Celebrex) and rofecoxib (Vioxx).